167 related articles for article (PubMed ID: 22310589)
21. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
[TBL] [Abstract][Full Text] [Related]
22. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Bayoumy A; Sobh M; Ghoneim M
Iran J Kidney Dis; 2008 Jan; 2(1):34-9. PubMed ID: 19367007
[TBL] [Abstract][Full Text] [Related]
23. Cyclosporine trough concentrations in predicting allograft rejection and renal toxicity up to 12 months after renal transplantation.
Min DI; Perry PJ; Chen HY; Hunsicker LG
Pharmacotherapy; 1998; 18(2):282-7. PubMed ID: 9545147
[TBL] [Abstract][Full Text] [Related]
24. Cyclosporine: from renal transplantation to autoimmune diseases.
Ponticelli C
Ann N Y Acad Sci; 2005 Jun; 1051():551-8. PubMed ID: 16126995
[TBL] [Abstract][Full Text] [Related]
25. [Safety in the switching traditional cyclosporin to microemulsion cyclosporin in stable renal transplant patients: cooperative study].
Milanés CL; Arminio A; Barrios Y; García-Ramírez R; Herrera J; León I; Salgado O; Terán M; Zschaeck D; Weisinger J
Invest Clin; 1995 Dec; 36(4):183-96. PubMed ID: 8589082
[TBL] [Abstract][Full Text] [Related]
26. Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year.
Neumayer HH; Budde K; Färber L; Haller P; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J; Luft FC
Clin Nephrol; 1996 May; 45(5):326-31. PubMed ID: 8738665
[TBL] [Abstract][Full Text] [Related]
27. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients.
Grimbert P; Baron C; Fruchaud G; Hemery F; Desvaux D; Buisson C; Chopin D; Dahmane D; Remy P; Pastural M; Abbou C; Weil B; Lang P
Transpl Int; 2002 Nov; 15(11):550-5. PubMed ID: 12461659
[TBL] [Abstract][Full Text] [Related]
28. Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.
Shabtai M; Ben-Haim M; Zemer D; Malinger-Saavedra P; Rosin D; Kuriansky J; Lustig S; Shabtai EL; Shapira Z; Ayalon A
Isr Med Assoc J; 2002 Nov; 4(11 Suppl):935-9. PubMed ID: 12455184
[TBL] [Abstract][Full Text] [Related]
29. Cyclosporine withdrawal improves long-term graft survival in renal transplantation.
Gallagher M; Jardine M; Perkovic V; Cass A; McDonald S; Petrie J; Eris J
Transplantation; 2009 Jun; 87(12):1877-83. PubMed ID: 19543068
[TBL] [Abstract][Full Text] [Related]
30. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients.
Kobashigawa JA; Patel J; Furukawa H; Moriguchi JD; Yeatman L; Takemoto S; Marquez A; Shaw J; Oeser BT; Subherwal S; Wu GW; Kawano J; Laks H
J Heart Lung Transplant; 2006 Apr; 25(4):434-9. PubMed ID: 16563974
[TBL] [Abstract][Full Text] [Related]
31. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
32. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen.
Irish W; Sherrill B; Brennan DC; Lowell J; Schnitzler M
Transplantation; 2003 Dec; 76(12):1686-90. PubMed ID: 14688516
[TBL] [Abstract][Full Text] [Related]
33. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
[TBL] [Abstract][Full Text] [Related]
34. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
[TBL] [Abstract][Full Text] [Related]
35. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up.
Greig P; Lilly L; Scudamore C; Erb S; Yoshida E; Kneteman N; Bain V; Ghent C; Marotta P; Grant D; Wall W; Tchervenkov J; Barkun J; Roy A; Marleau D; McAlister V; Peltekian K
Liver Transpl; 2003 Jun; 9(6):587-95. PubMed ID: 12783400
[TBL] [Abstract][Full Text] [Related]
36. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
[TBL] [Abstract][Full Text] [Related]
37. Cyclosporine versus tacrolimus maintenance therapy in renal transplant.
Alghamdi S; Nabi Z; Skolnik E; Alkorbi L; Albaqumi M
Exp Clin Transplant; 2011 Jun; 9(3):170-4. PubMed ID: 21649564
[TBL] [Abstract][Full Text] [Related]
38. Variable cyclosporine exposure: a risk factor for chronic allograft nephropathy and graft loss?
He X; Johnston A
Transplant Proc; 2004 Jun; 36(5):1321-6. PubMed ID: 15251323
[TBL] [Abstract][Full Text] [Related]
39. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion.
Filler G; Webb NJ; Milford DV; Watson AR; Gellermann J; Tyden G; Grenda R; Vondrak K; Hughes D; Offner G; Griebel M; Brekke IB; McGraw M; Balzar E; Friman S; Trompeter R
Pediatr Transplant; 2005 Aug; 9(4):498-503. PubMed ID: 16048603
[TBL] [Abstract][Full Text] [Related]
40. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
Baboolal K
Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
